Cancer Supportive Care Market

Rising cancer prevalence coupled with the increasing geriatric population is driving the market growth

The aging population, increased cancer incidence, and widespread use of chemotherapy in low- and middle-income areas are all driving forces in the market. Cancer treatment has been significantly impacted by the global COVID-19 pandemic. The American Society of Clinical Oncology reports that throughout the pandemic, there was a marked decrease in visits, cancer tests, surgeries, and therapy.

Additionally, there was a considerable decline in the number of hospital outpatient evaluation and management (E&M) visits (74%), new patient E&M visits (70%), and current patient E&M visits (60%) overall. However, the general state of affairs began to normalize in the majority of regions around the second quarter of 2021. Increasing geriatric population and rising cancer prevalence are two of the key reasons propelling market expansion. In the next twenty years, there will likely be 28.4 million new instances of cancer, up 47% from 2020, according to Globocan.

In addition, older people are more vulnerable to cancer; in developing nations, the average lifespan now exceeds 80 years.

Around two-thirds of all new cancer cases are diagnosed in persons 65 years of age and older, according to the SEER Database of the U.S. National Cancer Institute, demonstrating that aging can make people more susceptible to such diseases. Major firms are mainly concentrating on the development of novel targeted medicines for the treatment of cancer as a result of the surge in technical breakthroughs. It has fewer side effects than conventional therapies like chemotherapy. These elements may limit market expansion during the anticipated term. For instance, the U.S.

FDA granted Trodelvy (sacituzumab govitecan-hziy) expedited approval in April 2020 to Gilead Sciences, Inc.

Patients with triple-negative breast cancer are eligible to receive therapy with it. It is an antibody-drug combination that, unlike chemotherapy and other conventional treatments, only targets and kills certain infected cells through its poisonous chemical molecule. The popularity of biosimilars and generic medications is another issue impeding market expansion. Branded drug sales are being hampered by the introduction of biosimilar versions of popular medications. For instance, Pfizer's NYVEPRIA, a biosimilar to Amgen's NEULASTA, was approved in June 2020. Thus, driving the Cancer Supportive Care market revenue.

The increasing incidence of cancer globally is a primary driver of the Global Cancer Supportive Care Market Industry. As per estimates, cancer cases are projected to rise significantly, leading to a heightened demand for supportive care services. In 2024, the market is valued at approximately 20.9 USD Billion, reflecting the urgent need for comprehensive care solutions that address the physical, emotional, and psychological challenges faced by patients. This trend is likely to continue, with projections indicating that by 2035, the market could reach 27.4 USD Billion, highlighting the critical role of supportive care in enhancing patient quality of life.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Cancer Supportive Care Market dominated the global market in 2022 with 45.80% share. The market for cancer supportive care medications in North America is expected to develop significantly due to the quick uptake of pharmaceutical industry advancements. The dominance of North America in the cancer supportive care drug market will be sustained during the projected period by the existence of reputable vendors in the supportive care industry.

Further, the U.S. market of Cancer Supportive Care held the largest market share, and the Canada market of Cancer Supportive Care was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: CANCER SUPPORTIVE CARE MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe Cancer Supportive Care market accounts for the second-largest market share. The demand for cancer supportive care medications and palliative care has increased in the area due to the high rise in breast cancer cases among female patients. This factor is expected to drive the market's growth in Europe during the forecast period. Numerous private enterprises and governmental organizations are investing enormous sums in R&D operations in the oncology research sector to deliver more advanced and dependable treatment for cancer patients.

Further, the German market of Cancer Supportive Care held the largest market share, and the U.K market of Cancer Supportive Care was the fastest growing market in the European region

The Asia Pacific Cancer Supportive Care market is expected to register fastest CAGR from 2023 to 2032, due to the cancer industry's rising demand for supportive care. In this area, chemotherapy is frequently utilized to treat cancer patients. The market for cancer supportive care medications in Asia Pacific is anticipated to rise due to the increase in chemotherapies in metropolitan regions. Furthermore, the market's expansion in Asia Pacific will be fueled by rising vendor investments in oncology research.

Moreover, China’s market of Cancer Supportive Care held the largest market share, and the Indian market of Cancer Supportive Care was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Cancer Supportive Care, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Cancer Supportive Care industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Cancer Supportive Care industry to benefit clients and increase the market sector. In recent years, the Cancer Supportive Care industry has offered some of the most significant advantages to medicine. Major players in the Cancer Supportive Care market, including Amgen Inc., Baxter International Inc., F.

Hoffmann-La Roche Ltd., GlaxoSmithKline Plc (GSK) (Tesaro), Helsinn Healthcare, Heron Therapeutics, Johnson & Johnson (Janssen Global Services, LLC,), Merck KGAA, Novartis International AG (Sandoz), and Teva Pharmaceuticals., are attempting to increase market demand by investing in research and development operations.

A biopharmaceutical company called Imugene Ltd. (Imugene) is currently developing immuno-oncology vaccines. The company develops immunotherapies that stimulate the immune systems of cancer patients to find and eliminate malignancies. The company's pipeline drugs include HER-Vaxx, PD1-Vaxx, B-Vaxx, Vaxinia (CF33-hNIS), CHECKvacc (CF33+ hNIS+ PD-L1), PD-L1, VEGF, and IGF-1R for the treatment of various malignancies, including as gastric, breast, and lung cancers. Imugene, an Australian-based biotech company, announced in March 2022 that it had entered into a clinical trial collaboration and supply agreement with MSD, a subsidiary of Merck & Co., Inc., based in Kenilworth, NJ, USA.

The objective of the partnership is to assess the effectiveness and safety of Imugene's HER-Vaxx, a B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (trademarked as KEYTRUDA), for patients who have HER-2 positive gastric cancer.

A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. In addition to others, it offers medicines for the treatment of solid tumors, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. For the treatment of adult patients with a specific type of advanced cancer known as prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic), Novartis received FDA approval for Pluvicto in March 2022.